Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Dow Short-term Stock Market Trend Analysis - 6th Mar 21
Intel Rocket Lake EXPLODE on Launch - 11th Gen CPU's RUN VERY HOT Bad Cinebench R20 Scores - 6th Mar 21
US & UK Head for Post Coronavirus Pandemic Lockdown Inflationary Economic BOOM - 6th Mar 21
FED Balance Sheet Current State - 5th Mar 21
The Global Vaccine Race Against Time and Variants - 5th Mar 21
US Treasury Yields Rally May Trigger A Crazy Ivan Event (Again) In Stock Market - 5th Mar 21
After Gold’s Slide, What Happens to Miners? - 5th Mar 21
Racism Pandemic Why UK Black and Asians NOT Getting Vaccinated - NHS Covid-19 BAME - 5th Mar 21
Get Ready for Inflation Mega-trend to Surge 2021 - 4th Mar 21
Stocks, Gold – Rebound or Dead Cat Bounce? - 4th Mar 21
The Top Technologies That Are Transforming the Casino Industry - 4th Mar 21
How to Get RICH Crypto Mining Bitcoin, Ethereum With NiceHash - 4th Mar 21
Coronavirus Pandemic Vaccines Indicator Current State - 3rd Mar 21
AI Tech Stocks Investing 2021 Buy Ratings, Levels and Valuations Explained - 3rd Mar 21
Stock Market Bull Trend in Jeopardy - 3rd Mar 21
New Global Reserve Currency? - 3rd Mar 21
Gold To Monetary Base Ratio Says No Hyperinflation - 3rd Mar 21
US Fed Grilled about Its Unsound Currency, Digital Currency Schemes - 3rd Mar 21
The Case Against Inflation - 3rd Mar 21
How to Start Crypto Mining Bitcoins, Ethereum with Your Desktop PC, Laptop with NiceHash - 3rd Mar 21
AI Tech Stocks Investing Portfolio Buying Levels and Valuations 2021 Explained - 2nd Mar 21
There’s A “Chip” Shortage: And TSMC Holds All The Cards - 2nd Mar 21
Why now might be a good time to buy gold and gold juniors - 2nd Mar 21
Silver Is Close To Something Big - 2nd Mar 21
Bitcoin: Let's Put 2 Heart-Pounding Price Drops into Perspective - 2nd Mar 21
Gold Stocks Spring Rally 2021 - 2nd Mar 21
US Housing Market Trend Forecast 2021 - 2nd Mar 21
Covid-19 Vaccinations US House Prices Trend Indicator 2021 - 2nd Mar 21
How blockchain technology will change the online casino - 2nd Mar 21
How Much PC RAM Memory is Good in 2021, 16gb, 32gb or 64gb? - 2nd Mar 21
US Housing Market House Prices Momentum Analysis - 26th Feb 21
FOMC Minutes Disappoint Gold Bulls - 26th Feb 21
Kiss of Life for Gold - 26th Feb 21
Congress May Increase The Moral Hazard Building In The Stock Market - 26th Feb 21
The “Oil Of The Future” Is Set To Soar In 2021 - 26th Feb 21
The Everything Stock Market Rally Continues - 25th Feb 21
Vaccine inequality: A new beginning or another missed opportunity? - 25th Feb 21
What's Next Move For Silver, Gold? Follow US Treasuries and Commodities To Find Out - 25th Feb 21
Warren Buffett Buys a Copper Stock! - 25th Feb 21
Work From Home Inflationary US House Prices BOOM! - 25th Feb 21
Man Takes First Steps Towards Colonising Mars - Nasa Perseverance Rover in Jezero Crater - 25th Feb 21
Musk, Bezos And Cook Are Rushing To Lock In New Lithium Supply - 25th Feb 21
US Debt and Yield Curve (Spread between 2 year and 10 year US bonds) - 24th Feb 21
Should You Buy a Landrover Discovery Sport in 2021? - 24th Feb 21
US Housing Market 2021 and the Inflation Mega-trend - QE4EVER! - 24th Feb 21
M&A Most Commonly Used Software - 24th Feb 21
Is More Stock Market Correction Needed? - 24th Feb 21
VUZE XR Camera 180 3D VR Example Footage Video Image quality - 24th Feb 21
How to Protect Your Positions From A Stock Market Sell-Off Using Options - 24th Feb 21
Why Isn’t Retail Demand for Silver Pushing Up Prices? - 24th Feb 21
2 Stocks That Could Win Big In The Trillion Dollar Battery War - 24th Feb 21
US Economic Trends - GDP, Inflation and Unemployment Impact on House Prices 2021 - 23rd Feb 21
Why the Sky Is Not Falling in Precious Metals - 23rd Feb 21
7 Things Every Businessman Should Know - 23rd Feb 21
For Stocks, has the “Rational Bubble” Popped? - 23rd Feb 21
Will Biden Overheat the Economy and Gold? - 23rd Feb 21
Precious Metals Under Seige? - 23rd Feb 21
US House Prices Trend Forecast Review - 23rd Feb 21
Lithium Prices Soar As Tesla, Apple And Google Fight For Supply - 23rd Feb 21
Stock Markets Discounting Post Covid Economic Boom - 22nd Feb 21
Economics Is Why Vaccination Is So Hard - 22nd Feb 21
Pivotal Session In Stocks Bull Bear Battle - 22nd Feb 21
Gold’s Downtrend: Is This Just the Beginning? - 22nd Feb 21
The Most Exciting Commodities Play Of 2021? - 22nd Feb 21
How to Test NEW and Used GPU, and Benchmark to Make sure it is Working Properly - 22nd Feb 21
US House Prices Vaccinations Indicator - 21st Feb 21
S&P 500 Correction – No Need to Hold Onto Your Hat - 21st Feb 21
Gold Setting Up Major Bottom So Could We See A Breakout Rally Begin Soon? - 21st Feb 21
Owning Real Assets Amid Surreal Financial Markets - 21st Feb 21
Great Investment Ideas For 2021 - 21st Feb 21

Market Oracle FREE Newsletter

FIRST ACCESS to Nadeem Walayat’s Analysis and Trend Forecasts

Are Biotechnology Stocks Heading for A Downturn?

Companies / Healthcare Sector Nov 04, 2009 - 02:35 AM GMT

By: Oakshire_Financial

Companies

Best Financial Markets Analysis ArticleScience always looks to the future, and there's not much science that's more exciting than biotechnology.

After all, this is the field with big promises for better and longer lives for all of us through applied biology in agriculture, food science, and medicine. But although the term 'biotechnology' is often refers to futuristic genetic engineering, the industry is far broader than genetics alone.


The promise is there. But the risks are too.

Biotech is quite risky since promising drugs or treatments can fail to get government approval and thus the associated large research & development budget is wasted. Companies can spend literally hundreds of millions of dollars devising products that they eventually can't even sell. And that's for the products that actually get that far – there are all kinds of failed research efforts that fizzle just after they get started.

But for the ones that make it, an approved drug, treatment, or piece of equipment is a gold mine.

Biotech Leaves the S&P In Its Dust

The main index used to track the major biotechnology companies is the Biotechnology Index (BTK), an equal dollar weighted index which measures the performance of 20 companies involved in recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.

So how have these 20 companies been doing?

 

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%201.JPG

 

Pretty well when compared to the S&P 500 with a 30%+ gain even after a recent fall from 52 week highs.

It's clear that even if most other industries are mired in the doldrums of earnings (and expectations) mediocrity, people are still seeing promise in biotech.

But is the biotech boom over? Let's take a closer look...

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%202.JPG

 

In this daily chart of BTK, we see that the MACD and RSI indicators are dropping fast and are close to (or already in) the 'buy zone'.

However, it looks like there might be a bit more of a drop to come. That's based on two things we can see in this chart:

  1. We aren't yet seeing a reversal candlestick that would indicate a bottom is in, and
  2. There's no obvious support at this price level.

We could see some support at 835, however as the market previously turned around at that level.

So if we're going to start positioning ourselves for a future buy at some point, what's the best way to do it?


Biotech ETFs For Diversity's Sake

Due to the extreme risks of holding single biotech stocks (the drops and rises can be truly heart-stopping – especially if you're caught on the wrong side of them!) it's better to hedge your risk with a good ETF (Exchange Traded Fund) instead.

The following chart compares 6 different biotech ETFs against the BTK index itself...


http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%203.JPG

As you can see, there's only one fund (First Trust Amex Biotechnology Trust, symbol FBT) that's doing as well as BTK itself. In fact, it's mirroring BTK which isn't much of a surprise when you learn that it was designed to do so.

The other funds are not performing nearly as well despite their very different strategies.

The iShares Nasdaq Biotechnology Trust (IBB – the pink line shown in the comparison chart) holds the largest number of stocks (approximately 120+) of any of the ETFs and it's also the most actively traded. You're up about 12% over the year with their strategy.

That's still better than HOLDRS Biotech ETF (BBH – the black line) which is very unevenly balanced due to its "grantor trust" status and holds few stocks. This cripples its trading strategy as it can't alter its underlying holdings except as a result of corporate actions.

But the SPDR S&P Biotech (XBI – the purple line) holds up the bottom of the chart. How this fund could lose money when BTK is performing so well is stunning. Theoretically this fund follows a similar strategy as top performer FBT but clearly the managers have not been on the ball at all.

The others are the middle of the pack, and it seems that FBT is the vehicle of choice for trading (or investing in) the biotechnology sector.


Broaden Your Horizons For Less Risk


Biotech is frequently considered a subset of the larger healthcare sector.

So if you still think biotech is too risky, you could look at healthcare too. After all, people are still getting sick and injured (and getting old) no matter what the economy does.

Here's the NYSE Healthcare Index (NYP), which is comprised of 108 different holdings as of this writing...

 

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%204.JPG

 

As you can see, this index is holding up even better than BTK, although it looks to also be ripe for a bit of a fall in the near future too.

If the bull trend remains intact, a logical buying point would be at the 50 day moving average.

So what's doing best in that sector?


http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%205.JPG

Well, First Trust is again a clear winner with its FirstTrust AlphaDEX Healthcare fund (FXH). It's dramatically outperforming everything else in this comparison chart including the NYP index itself.

This ETF is designed to track the StrataQuant Health Care which employs the AlphaDEX stock selection methodology to select stocks from the Russell 1000 Index. This AlphaDEX strategy is based on a large number of fundamental factors, but whatever they're doing with that methodology, it's obviously working wonderfully well.

Meanwhile, the next closest contender is the Rydex S&P Equal Weight Health Care ETF (RYH) which seeks to replicate the performance of the S&P Equal Weight Index Health Care index (yet another lesser known but more impressive index than NYP).

So there you have it. The biotech (and healthcare) sectors look likely to drop a bit in the next few days or even weeks. But you now have some targeted 'buy' levels for the better-known benchmark indexes as well as the best performing ETF in each area.

Remember that science (and healthcare) is unlikely to take a backward step no matter how foolish the decisions coming from Washington. That makes these sectors relatively safe bets in an otherwise uncertain economy.

Good investing,

Nick Thomas
Analyst, Oxbury Research

Nick Thomas is a seasoned veteran of technical analysis and has mastered all intra-day trading in stocks, options, futures and forex. He prefers to scout investments as one asset class of many and shapes his investment strategies accordingly. He writes extensively about offshore banking and offshore tax havens and is active in the career development field of independent investment research.

Oxbury Research originally formed as an underground investment club, Oxbury Publishing is comprised of a wide variety of Wall Street professionals - from equity analysts to futures floor traders – all independent thinkers and all capital market veterans.

© 2009 Copyright Oxbury Research - All Rights Reserved
Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Oxbury Research Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules